Figure 5.

Efficacy of YYB-101 in a mouse ovarian cancer xenograft model. A2780/luc cells (1 × 10⁷) were intraperitoneally injected into mice, which were randomly divided into four groups (n = 6 per group). Control mice were injected intravenously with phosphate-buffered saline (PBS). Where indicated, mice were injected with 40 mg/kg YYB-101 twice weekly and with 10 mg/kg paclitaxel once weekly. (A) Schematic of experimental design. (B) Monitoring of tumor progression using in vivo Imaging System (IVIS) bioluminescence imaging once weekly. Mice were injected intraperitoneally with 75 mg/kg luciferin and bioluminescence images were obtained using an IVIS imaging device. Representative images 3, 16, and 30 days after tumor implantation are shown. (C) Quantitation of total bioluminescence using Living Image software. Error bars represent ± standard error of the mean (SEM). The t-test p-value was the comparison between co-treatment with control group (^**p < 0.01). (D) Kaplan-Meier analysis of survival of various groups of mice for up to 100 days after cancer cell implantation. (E) Median survival was calculated using Kaplan-Meier statistic. Log-Rank, p < 0.001 for paclitaxel and combination treatment groups compared with control group. (F) Body weight change of mice for 30 days after tumor implantation. Values represent the mean ± standard deviation (SD). Average body weight of drug treatment groups was not significantly different compared with control group.